Haemonetics Corporation (NYSE:HAE) Accelerates Expansion After Vivasure Deal, Near-Term Upside Likely
![]() |
Haemonetics moves from portfolio pruning into targeted M&A and operational consolidation, positioning margin expansion while technical momentum suggests a near-term bullish bias. The current valuation as determined by WMDST shows the stock under-valued relative to fundamentals. |










